Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

imuna pharm, a.s., Šarišské michaľany array - 875 mannitol - infuzní roztok - 200mg/ml - mannitol

Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

fresenius kabi s.r.o., praha array - 4957 monohydrÁt glukosy - infuzní roztok - 200mg/ml - cukry

Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

merck sharp & dohme b.v., haarlem array - 18524 polysacharid streptococcus pneumoniae sÉrotypu 1; 22017 polysacharid streptococcus pneumoniae sÉrotypu 2; 18824 polysacharid streptococcus pneumoniae sÉrotypu 3; 16707 polysacharid streptococcus pneumoniae sÉrotypu 4; 18525 polysacharid streptococcus pneumoniae sÉrotypu 5; 16708 polysacharid streptococcus pneumoniae sÉrotypu 6b; 18526 polysacharid streptococcus pneumoniae sÉrotypu 7f; 22018 polysacharid streptococcus pneumoniae sÉrotypu 8; 22019 polysacharid streptococcus pneumoniae sÉrotypu 9n; 16709 polysacharid streptococcus pneumoniae sÉrotypu 9v; 22020 polysacharid streptococcus pneumoniae sÉrotypu 10a; 22021 polysacharid streptococcus pneumoniae sÉrotypu 11a; 22022 polysacharid streptococcus pneumoniae sÉrotypu 12f; 16710 polysacharid streptococcus pneumoniae sÉrotypu 14; 22023 polysacharid streptococcus pneumoniae sÉrotypu 15b; 22024 polysacharid streptococcus pneumoniae sÉrotypu 17f; 16711 polysacharid streptococcus pneumoniae sÉrotypu 18c; 16712 polysacharid streptococcus pneumoniae sÉrotypu 19f; 18826 polysacharid streptococcus pneumoniae sÉrotypu 19a; 22025 polysacharid streptococcus pneumoniae sÉrotypu 20; 22026 polysacharid streptococcus pneumoniae sÉrotypu 22f; 16713 polysacharid streptococcus pneumoniae sÉrotypu 23f; 22027 polysacharid streptococcus pneumoniae sÉrotypu 33f - injekční roztok v předplněné injekční stříkačce - pneumococcus, purifikovanÉ polysacharidovÉ antigeny

Evropská unie - čeština - EMA (European Medicines Agency)

sanofi b.v. - olipudase alfa - acid sphingomyelinase deficiency (asmd) type a/b or type b - jiné zažívací trakt a produkty metabolismu, - xenpozyme is indicated as an enzyme replacement therapy for the treatment of non-central nervous system (cns) manifestations of acid sphingomyelinase deficiency (asmd) in paediatric and adult patients with type a/b or type b.

Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

zentiva, k.s., praha array - 11275 drospirenon; 578 ethinylestradiol - potahovaná tableta - 3mg/0,02mg - drospirenon a ethinylestradiol

Evropská unie - čeština - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - belatacept - graft rejection; kidney transplantation - imunosupresiva - nulojix, in combination with corticosteroids and a mycophenolic acid (mpa), is indicated for prophylaxis of graft rejection in adult recipients of a renal transplant.

Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

bayer ag, leverkusen array - 12 kyselina acetylsalicylovÁ - enterosolventní tableta - 100mg - kyselina acetylsalicylovÁ

Evropská unie - čeština - EMA (European Medicines Agency)

eurocept international bv - kyselina carglumová - hyperammonemia; amino acid metabolism, inborn errors - jiné zažívací trakt a produkty metabolismu, - ucedane is indicated in treatment of:hyperammonaemia due to n-acetylglutamate synthase primary deficiency;hyperammonaemia due to isovaleric acidaemia;hyperammonaemia due to methymalonic acidaemia;hyperammonaemia due to propionic acidaemia.

Evropská unie - čeština - EMA (European Medicines Agency)

taw pharma (ireland) limited - hydrochlorid klopidogrelu - peripheral vascular diseases; stroke; myocardial infarction; acute coronary syndrome - antitrombotické činidla - , , , , secondary prevention of atherothrombotic events, , clopidogrel is indicated in: , - adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. , - adult patients suffering from acute coronary syndrome:,    - non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). ,     - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy. , , in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is), clopidogrel in combination with asa is indicated in:, - adult patients with moderate to high-risk tia (abcd2  score ≥4) or minor is (nihss  ≤3) within 24 hours of either the tia or is event.  , , prevention of atherothrombotic and thromboembolic events in atrial fibrillation, in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. , , for further information please refer to section 5. , , ,.

Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

av medical cz s.r.o., praha array - 19569 triturace norgestimÁtu 0.324%; 19570 triturace ethinylestradiolu 0.33% - tableta - 0,25mg/0,035mg - norgestimÁt a ethinylestradiol